RecruitingPhase 3NCT07365332

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Sponsor

Inhibikase Therapeutics

Enrollment

486 participants

Start Date

Apr 23, 2026

Study Type

INTERVENTIONAL

Conditions

Pulmonary Arterial Hypertension

Summary

This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called IKT-001 and a drug called Placebo for people with pulmonary arterial hypertension. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.